Search research articles
Contact Us
Filters
Showing results (11-20 of 122) with videos related to
Page
of 13
Sort By:
Expert Review of Neurotherapeutics
|
July 24, 2019
Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures
Lorena Lechuga, David Neal Franz
Expert Opinion on Pharmacotherapy
|
April 28, 2020
Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA)
Daniel Ebrahimi-Fakhari, David Neal Franz
Journal of Clinical Nursing
|
March 11, 2004
Primary care: questionnaire survey of alternative forms of patient and nurse face-to-face consultations
Shane William Pascoe, Richard David Neal
The American Journal of Psychiatry
|
May 5, 2009
Chest pain in a young patient treated with prazosin for PTSD
Syeda Shazia Nuzhat, David Neal Osser
BMJ (Clinical Research Ed.)
|
September 7, 2018
What should doctors say to men asking for a PSA test?
Martin Roland, David Neal, Richard Buckley
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
|
October 12, 2018
mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex
David Neal Franz, Darcy Andrew Krueger
Neuropsychiatric Disease and Treatment
|
September 8, 2016
Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
Jamie K Capal, David Neal Franz
Neurology
|
June 21, 2019
Everolimus for cognition/autism in children with tuberous sclerosis complex: Definitive outcomes deferred
Kevin C Ess, David Neal Franz
Current Neurology and Neuroscience Reports
|
May 1, 2012
Molecular therapies for tuberous sclerosis and neurofibromatosis
David Neal Franz, Brian D Weiss
World Journal of Urology
|
August 4, 2004
Mucus production after transposition of intestinal segments into the urinary tract
James N'Dow, Jeffrey Pearson, David Neal
Page
of 13
Search research articles
Search
Showing results (11-20 of 122) with videos related to
Sort By:
Page
of 13
Expert Review of Neurotherapeutics
|
July 24, 2019
Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures
Lorena Lechuga, David Neal Franz
Expert Opinion on Pharmacotherapy
|
April 28, 2020
Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA)
Daniel Ebrahimi-Fakhari, David Neal Franz
Journal of Clinical Nursing
|
March 11, 2004
Primary care: questionnaire survey of alternative forms of patient and nurse face-to-face consultations
Shane William Pascoe, Richard David Neal
The American Journal of Psychiatry
|
May 5, 2009
Chest pain in a young patient treated with prazosin for PTSD
Syeda Shazia Nuzhat, David Neal Osser
BMJ (Clinical Research Ed.)
|
September 7, 2018
What should doctors say to men asking for a PSA test?
Martin Roland, David Neal, Richard Buckley
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
|
October 12, 2018
mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex
David Neal Franz, Darcy Andrew Krueger
Neuropsychiatric Disease and Treatment
|
September 8, 2016
Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
Jamie K Capal, David Neal Franz
Neurology
|
June 21, 2019
Everolimus for cognition/autism in children with tuberous sclerosis complex: Definitive outcomes deferred
Kevin C Ess, David Neal Franz
Current Neurology and Neuroscience Reports
|
May 1, 2012
Molecular therapies for tuberous sclerosis and neurofibromatosis
David Neal Franz, Brian D Weiss
World Journal of Urology
|
August 4, 2004
Mucus production after transposition of intestinal segments into the urinary tract
James N'Dow, Jeffrey Pearson, David Neal
Page
of 13